Monday, June 4, 2018

PharmaMar Presents New Results with Lurbinectedin as a Single Agent in Patients with Recurrent Small-cell Lung Cancer at ASCO 2018

http://mma.prnewswire.com/media/624563/PharmaMar_Logo.jpg?p=captionMADRID, June 4, 2018 /PRNewswire/ -- Abstract #8570 The phase II basket trial, which began recruiting 15 patients with recurrent small-cell lung cancer, was increased to target enrolment of 100 after obtaining a positive response. In a total of 61 patients,...




from PR Newswire: //https://ift.tt/2sExOHu

No comments:

Post a Comment